TrialSignal
Clinical trial intelligence report
A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02135640
Status
COMPLETED
Phase
PHASE1
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
This study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of denosumab administered subcutaneously to healthy adults in China.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02135640
Indication
Osteoporosis
Modality
monoclonal antibody
Target
denosumab 60mg, denosumab 120 mg, placebo
Intervention
denosumab 60mg, denosumab 120 mg, placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.